This report was first published by Endpoints News. To see the original version, click here
Sanofi on Saturday shared more mixed efficacy results from a Phase 3 atopic dermatitis program for its anti-OX40 ligand monoclonal antibody, further eroding Wall Street’s already waning confidence in the candidate.
The French pharma also revealed that one more patient treated with amlitelimab developed Kaposi’s sarcoma, a type of vascular tumor, bringing the total to two cases across the drug’s development history.
您已阅读16%（507字），剩余84%（2578字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。